2025 Q2 -tulosraportti
199 päivää sitten
‧37 min
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 800 | - | - | ||
| 18 867 | - | - | ||
| 3 000 | - | - | ||
| 5 963 | - | - | ||
| 1 021 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·3 t sittenOver the coming months, I hope and believe this will rise a lot. I'm being realistic and hope to see the 10-mark 🙏·1 t sitten12 kroner soon - revenue of 150 mill creates insane buying pressure. Impossible to stop. Acquisition gives 60-80 kroner
·4 t sittenThis partnership, which is not part of Circio's internal pipeline, could yield results this spring. NeoRegen's project with CWD v ABio Tech and with Circio, which went in vivo in July 2025, after good in vitro results, is expected to be completed 1 year from April 2025. This is from NeoRegen's website and they do not work with other external partners than these 3.
·4 t sittenThere are several recent examples where Big Pharma has chosen to acquire technology before clinical studies and results. As far as I can see, recently, it has mainly been about: - CRISPR platforms - RNA delivery systems (Circio) - Gene therapy vectors The reason this happens, i.e., acquisitions before it's confirmed to work in humans, is that BP believes the value lies in the biological mechanism (e.g., CircVec) and not in a single drug or area of use. And here, Circio has already asserted itself. ----> Platform technologies (CircVec) are today far more attractive than individual drugs. <---- Circio's CircVec is a so-called "expression-enhancement system" for gene therapy, which means the platform: - Can improve many already existing AAV programs. - Can be used in many different pathological areas. - Can be integrated into many different, already existing, pipelines. -------------------------------------------------- "40x higher protein expression and ~75x longer half-life", Erik and Thomas announced on February 26th via webcast. If that were to hold true clinically, which I believe is likely (not just because of Erik W's eminent self-confidence). In practice, it would mean that BP could reduce the virus dose, decrease toxicity, and increase treatment efficacy. (This should be regarded as absolutely revolutionary improvements in gene therapy). This would be invaluable and strategically very(!) valuable for a company with several different gene therapy programs. And this is where Eli Lilly comes in. As Eli Lilly's pipeline is now estimated to consist of one third of various gene therapeutic methods and programs. Eli Lilly has made and is still making a comprehensive investment in this area. (Many billions of dollars) ----------------------------------------- I dare to believe that this "case" is far more certain than uncertain, but of course, it's important to try to be critical when possible. The biggest and perhaps only reasonable counter-argument to success (acquisition) is that there is no clinical data yet. But, that counter-argument shrinks when looking at all the unique factors presented and where things could go wrong during clinical trials. Immune response, liver toxicity, and functional tissue specificity are the biggest known potential problems that can arise in RNA and gene therapy today. (circular RNA should not cause any of that, in itself) One might also consider it a standing counter-argument, meaning it always applies to research in Biotech, and therefore it doesn't necessarily have to be relevant in individual and unique cases, at all. It happens that In vivo, in mice, shows good results. Only to then fail in humans. ----But, all things considered, that does not seem to be the probable outcome for Circio----- Furthermore, I find it hard to see Erik as self-confident as he appears, if it weren't justified. Sometimes it's not harder than that. My gut feeling is still strongly positive towards CRNA.·3 t sitten · MuokattuTypical biotech acquisition sequence usually looks like this; 1. Feasibility 2. Research collaboration 3. License agreement 4. Clinical proof of concept 5. Acquisition Technology that is strategically crucial (for the buyer), competition among different companies, and that the platform is considered able to set a new standard in its field. Is what speaks for an early acquisition.
·4 t sittenFor those who do not understand what CNS diseases are and Circio's opportunities: This means that the technology **can become relevant for diseases in the brain and spinal cord**. CNS stands for **central nervous system**, i.e., **the central nervous system**: the brain and the spinal cord. ([NCBI][1]) **CNS diseases** are therefore diseases that affect these areas. Examples are: * Parkinson's disease * multiple sclerosis (MS) * ALS * certain hereditary neurodegenerative and metabolic diseases * brain tumors * epilepsy * injuries or diseases in the spinal cord. ([NINDS][2]) When Circio says that their data opens up opportunities within CNS diseases, in practice this means: **1. They have seen signals for gene expression in brain/CNS.** Circio reported in November 2025 that they had “emerging positive data in brain / CNS” and that they saw around **4 times increased expression in the brain** in their preclinical data. ([Circio][3]) **2. It is especially important because CNS is difficult to treat.** Diseases in the brain and spinal cord are often challenging for gene therapy because one must achieve sufficient delivery and expression in the correct tissue, while dose and side effects are kept down. AAV is widely used in gene therapy precisely to deliver genetic material to cells, but dose, immune response, and safety are important limitations. ([NCBI][4]) **3. If circVec actually provides better expression in CNS, it can make several diseases commercially and medically more realistic to treat.** This is what is meant by “opens up opportunities”: not that the diseases are solved, but that the platform might be used in more indications than just heart and eye. Circio itself has pointed to CNS-related areas and listed disease examples such as Tay-Sachs, Krabbe, Gaucher and neurodegenerative diseases in its presentations. ([Circio][3]) The simple version is: **Before:** Circio primarily had strong data in heart and eye. **Now:** They suggest that the technology can also work in the brain. **Meaning:** Then the market and application area become much larger. ([Circio][3]) This does not mean that they have a finished CNS medicine. It means that they may have a **platform** that can also be used in diseases of the central nervous system, if further data confirms this. ([Circio][3]) I can also set up a simple overview of which **CNS diseases might be most commercially interesting for Circio**. [1]: https://www.ncbi.nlm.nih.gov/mesh?Cmd=DetailsSearch&Db=mesh&Term=%22Central+Nervous+System+Diseases%22%5BMeSH+Terms%5D&utm_source=chatgpt.com "Central Nervous System Diseases - MeSH - NCBI - NIH" [2]: https://www.ninds.nih.gov/health-information/disorders?utm_source=chatgpt.com "All Disorders" [3]: https://www.circio.com/en/circio-presents-data-that-further-strengthens-and-broadens-its-circvec-circular-rna-expression-platform/?utm_source=chatgpt.com "Circio presents data that further strengthens and broadens ..." [4]: https://www.ncbi.nlm.nih.gov/books/NBK594993/?utm_source=chatgpt.com "Chapter 8 Central Nervous System - Nursing Pharmacology"- ·4 t sittenThis is what we know: 1. The Big Pharma deal is real external validation of circVec. Circio has publicly announced that they have entered into a fully funded feasibility study with a “major global pharmaceutical corporation”. The study concerns testing of circVec-enhanced gene therapy with AAV in a specific therapeutic area. 2. The work is performed at Circio, and the partner pays. It has been explicitly stated that the project will be performed by Circio and is fully funded by the pharmaceutical company. 3. CNS is now a real focus area for circVec. Circio has announced that they have for the first time shown benefit in the brain/brain, and that this opens up opportunities within CNS diseases. In their presentations, CNS has also been included as a priority area along with heart and eye. 4. Relevant data will be available in 2026, including CNS-related data points. The Q1 2026 presentation shows milestones for in vivo reporter data in heart, eye & CNS, as well as further disease model data and results from the feasibility study later in 2026.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q2 -tulosraportti
199 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 t sittenOver the coming months, I hope and believe this will rise a lot. I'm being realistic and hope to see the 10-mark 🙏·1 t sitten12 kroner soon - revenue of 150 mill creates insane buying pressure. Impossible to stop. Acquisition gives 60-80 kroner
- ·4 t sittenThis partnership, which is not part of Circio's internal pipeline, could yield results this spring. NeoRegen's project with CWD v ABio Tech and with Circio, which went in vivo in July 2025, after good in vitro results, is expected to be completed 1 year from April 2025. This is from NeoRegen's website and they do not work with other external partners than these 3.
- ·4 t sittenThere are several recent examples where Big Pharma has chosen to acquire technology before clinical studies and results. As far as I can see, recently, it has mainly been about: - CRISPR platforms - RNA delivery systems (Circio) - Gene therapy vectors The reason this happens, i.e., acquisitions before it's confirmed to work in humans, is that BP believes the value lies in the biological mechanism (e.g., CircVec) and not in a single drug or area of use. And here, Circio has already asserted itself. ----> Platform technologies (CircVec) are today far more attractive than individual drugs. <---- Circio's CircVec is a so-called "expression-enhancement system" for gene therapy, which means the platform: - Can improve many already existing AAV programs. - Can be used in many different pathological areas. - Can be integrated into many different, already existing, pipelines. -------------------------------------------------- "40x higher protein expression and ~75x longer half-life", Erik and Thomas announced on February 26th via webcast. If that were to hold true clinically, which I believe is likely (not just because of Erik W's eminent self-confidence). In practice, it would mean that BP could reduce the virus dose, decrease toxicity, and increase treatment efficacy. (This should be regarded as absolutely revolutionary improvements in gene therapy). This would be invaluable and strategically very(!) valuable for a company with several different gene therapy programs. And this is where Eli Lilly comes in. As Eli Lilly's pipeline is now estimated to consist of one third of various gene therapeutic methods and programs. Eli Lilly has made and is still making a comprehensive investment in this area. (Many billions of dollars) ----------------------------------------- I dare to believe that this "case" is far more certain than uncertain, but of course, it's important to try to be critical when possible. The biggest and perhaps only reasonable counter-argument to success (acquisition) is that there is no clinical data yet. But, that counter-argument shrinks when looking at all the unique factors presented and where things could go wrong during clinical trials. Immune response, liver toxicity, and functional tissue specificity are the biggest known potential problems that can arise in RNA and gene therapy today. (circular RNA should not cause any of that, in itself) One might also consider it a standing counter-argument, meaning it always applies to research in Biotech, and therefore it doesn't necessarily have to be relevant in individual and unique cases, at all. It happens that In vivo, in mice, shows good results. Only to then fail in humans. ----But, all things considered, that does not seem to be the probable outcome for Circio----- Furthermore, I find it hard to see Erik as self-confident as he appears, if it weren't justified. Sometimes it's not harder than that. My gut feeling is still strongly positive towards CRNA.·3 t sitten · MuokattuTypical biotech acquisition sequence usually looks like this; 1. Feasibility 2. Research collaboration 3. License agreement 4. Clinical proof of concept 5. Acquisition Technology that is strategically crucial (for the buyer), competition among different companies, and that the platform is considered able to set a new standard in its field. Is what speaks for an early acquisition.
- ·4 t sittenFor those who do not understand what CNS diseases are and Circio's opportunities: This means that the technology **can become relevant for diseases in the brain and spinal cord**. CNS stands for **central nervous system**, i.e., **the central nervous system**: the brain and the spinal cord. ([NCBI][1]) **CNS diseases** are therefore diseases that affect these areas. Examples are: * Parkinson's disease * multiple sclerosis (MS) * ALS * certain hereditary neurodegenerative and metabolic diseases * brain tumors * epilepsy * injuries or diseases in the spinal cord. ([NINDS][2]) When Circio says that their data opens up opportunities within CNS diseases, in practice this means: **1. They have seen signals for gene expression in brain/CNS.** Circio reported in November 2025 that they had “emerging positive data in brain / CNS” and that they saw around **4 times increased expression in the brain** in their preclinical data. ([Circio][3]) **2. It is especially important because CNS is difficult to treat.** Diseases in the brain and spinal cord are often challenging for gene therapy because one must achieve sufficient delivery and expression in the correct tissue, while dose and side effects are kept down. AAV is widely used in gene therapy precisely to deliver genetic material to cells, but dose, immune response, and safety are important limitations. ([NCBI][4]) **3. If circVec actually provides better expression in CNS, it can make several diseases commercially and medically more realistic to treat.** This is what is meant by “opens up opportunities”: not that the diseases are solved, but that the platform might be used in more indications than just heart and eye. Circio itself has pointed to CNS-related areas and listed disease examples such as Tay-Sachs, Krabbe, Gaucher and neurodegenerative diseases in its presentations. ([Circio][3]) The simple version is: **Before:** Circio primarily had strong data in heart and eye. **Now:** They suggest that the technology can also work in the brain. **Meaning:** Then the market and application area become much larger. ([Circio][3]) This does not mean that they have a finished CNS medicine. It means that they may have a **platform** that can also be used in diseases of the central nervous system, if further data confirms this. ([Circio][3]) I can also set up a simple overview of which **CNS diseases might be most commercially interesting for Circio**. [1]: https://www.ncbi.nlm.nih.gov/mesh?Cmd=DetailsSearch&Db=mesh&Term=%22Central+Nervous+System+Diseases%22%5BMeSH+Terms%5D&utm_source=chatgpt.com "Central Nervous System Diseases - MeSH - NCBI - NIH" [2]: https://www.ninds.nih.gov/health-information/disorders?utm_source=chatgpt.com "All Disorders" [3]: https://www.circio.com/en/circio-presents-data-that-further-strengthens-and-broadens-its-circvec-circular-rna-expression-platform/?utm_source=chatgpt.com "Circio presents data that further strengthens and broadens ..." [4]: https://www.ncbi.nlm.nih.gov/books/NBK594993/?utm_source=chatgpt.com "Chapter 8 Central Nervous System - Nursing Pharmacology"
- ·4 t sittenThis is what we know: 1. The Big Pharma deal is real external validation of circVec. Circio has publicly announced that they have entered into a fully funded feasibility study with a “major global pharmaceutical corporation”. The study concerns testing of circVec-enhanced gene therapy with AAV in a specific therapeutic area. 2. The work is performed at Circio, and the partner pays. It has been explicitly stated that the project will be performed by Circio and is fully funded by the pharmaceutical company. 3. CNS is now a real focus area for circVec. Circio has announced that they have for the first time shown benefit in the brain/brain, and that this opens up opportunities within CNS diseases. In their presentations, CNS has also been included as a priority area along with heart and eye. 4. Relevant data will be available in 2026, including CNS-related data points. The Q1 2026 presentation shows milestones for in vivo reporter data in heart, eye & CNS, as well as further disease model data and results from the feasibility study later in 2026.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 800 | - | - | ||
| 18 867 | - | - | ||
| 3 000 | - | - | ||
| 5 963 | - | - | ||
| 1 021 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
2025 Q2 -tulosraportti
199 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 t sittenOver the coming months, I hope and believe this will rise a lot. I'm being realistic and hope to see the 10-mark 🙏·1 t sitten12 kroner soon - revenue of 150 mill creates insane buying pressure. Impossible to stop. Acquisition gives 60-80 kroner
- ·4 t sittenThis partnership, which is not part of Circio's internal pipeline, could yield results this spring. NeoRegen's project with CWD v ABio Tech and with Circio, which went in vivo in July 2025, after good in vitro results, is expected to be completed 1 year from April 2025. This is from NeoRegen's website and they do not work with other external partners than these 3.
- ·4 t sittenThere are several recent examples where Big Pharma has chosen to acquire technology before clinical studies and results. As far as I can see, recently, it has mainly been about: - CRISPR platforms - RNA delivery systems (Circio) - Gene therapy vectors The reason this happens, i.e., acquisitions before it's confirmed to work in humans, is that BP believes the value lies in the biological mechanism (e.g., CircVec) and not in a single drug or area of use. And here, Circio has already asserted itself. ----> Platform technologies (CircVec) are today far more attractive than individual drugs. <---- Circio's CircVec is a so-called "expression-enhancement system" for gene therapy, which means the platform: - Can improve many already existing AAV programs. - Can be used in many different pathological areas. - Can be integrated into many different, already existing, pipelines. -------------------------------------------------- "40x higher protein expression and ~75x longer half-life", Erik and Thomas announced on February 26th via webcast. If that were to hold true clinically, which I believe is likely (not just because of Erik W's eminent self-confidence). In practice, it would mean that BP could reduce the virus dose, decrease toxicity, and increase treatment efficacy. (This should be regarded as absolutely revolutionary improvements in gene therapy). This would be invaluable and strategically very(!) valuable for a company with several different gene therapy programs. And this is where Eli Lilly comes in. As Eli Lilly's pipeline is now estimated to consist of one third of various gene therapeutic methods and programs. Eli Lilly has made and is still making a comprehensive investment in this area. (Many billions of dollars) ----------------------------------------- I dare to believe that this "case" is far more certain than uncertain, but of course, it's important to try to be critical when possible. The biggest and perhaps only reasonable counter-argument to success (acquisition) is that there is no clinical data yet. But, that counter-argument shrinks when looking at all the unique factors presented and where things could go wrong during clinical trials. Immune response, liver toxicity, and functional tissue specificity are the biggest known potential problems that can arise in RNA and gene therapy today. (circular RNA should not cause any of that, in itself) One might also consider it a standing counter-argument, meaning it always applies to research in Biotech, and therefore it doesn't necessarily have to be relevant in individual and unique cases, at all. It happens that In vivo, in mice, shows good results. Only to then fail in humans. ----But, all things considered, that does not seem to be the probable outcome for Circio----- Furthermore, I find it hard to see Erik as self-confident as he appears, if it weren't justified. Sometimes it's not harder than that. My gut feeling is still strongly positive towards CRNA.·3 t sitten · MuokattuTypical biotech acquisition sequence usually looks like this; 1. Feasibility 2. Research collaboration 3. License agreement 4. Clinical proof of concept 5. Acquisition Technology that is strategically crucial (for the buyer), competition among different companies, and that the platform is considered able to set a new standard in its field. Is what speaks for an early acquisition.
- ·4 t sittenFor those who do not understand what CNS diseases are and Circio's opportunities: This means that the technology **can become relevant for diseases in the brain and spinal cord**. CNS stands for **central nervous system**, i.e., **the central nervous system**: the brain and the spinal cord. ([NCBI][1]) **CNS diseases** are therefore diseases that affect these areas. Examples are: * Parkinson's disease * multiple sclerosis (MS) * ALS * certain hereditary neurodegenerative and metabolic diseases * brain tumors * epilepsy * injuries or diseases in the spinal cord. ([NINDS][2]) When Circio says that their data opens up opportunities within CNS diseases, in practice this means: **1. They have seen signals for gene expression in brain/CNS.** Circio reported in November 2025 that they had “emerging positive data in brain / CNS” and that they saw around **4 times increased expression in the brain** in their preclinical data. ([Circio][3]) **2. It is especially important because CNS is difficult to treat.** Diseases in the brain and spinal cord are often challenging for gene therapy because one must achieve sufficient delivery and expression in the correct tissue, while dose and side effects are kept down. AAV is widely used in gene therapy precisely to deliver genetic material to cells, but dose, immune response, and safety are important limitations. ([NCBI][4]) **3. If circVec actually provides better expression in CNS, it can make several diseases commercially and medically more realistic to treat.** This is what is meant by “opens up opportunities”: not that the diseases are solved, but that the platform might be used in more indications than just heart and eye. Circio itself has pointed to CNS-related areas and listed disease examples such as Tay-Sachs, Krabbe, Gaucher and neurodegenerative diseases in its presentations. ([Circio][3]) The simple version is: **Before:** Circio primarily had strong data in heart and eye. **Now:** They suggest that the technology can also work in the brain. **Meaning:** Then the market and application area become much larger. ([Circio][3]) This does not mean that they have a finished CNS medicine. It means that they may have a **platform** that can also be used in diseases of the central nervous system, if further data confirms this. ([Circio][3]) I can also set up a simple overview of which **CNS diseases might be most commercially interesting for Circio**. [1]: https://www.ncbi.nlm.nih.gov/mesh?Cmd=DetailsSearch&Db=mesh&Term=%22Central+Nervous+System+Diseases%22%5BMeSH+Terms%5D&utm_source=chatgpt.com "Central Nervous System Diseases - MeSH - NCBI - NIH" [2]: https://www.ninds.nih.gov/health-information/disorders?utm_source=chatgpt.com "All Disorders" [3]: https://www.circio.com/en/circio-presents-data-that-further-strengthens-and-broadens-its-circvec-circular-rna-expression-platform/?utm_source=chatgpt.com "Circio presents data that further strengthens and broadens ..." [4]: https://www.ncbi.nlm.nih.gov/books/NBK594993/?utm_source=chatgpt.com "Chapter 8 Central Nervous System - Nursing Pharmacology"
- ·4 t sittenThis is what we know: 1. The Big Pharma deal is real external validation of circVec. Circio has publicly announced that they have entered into a fully funded feasibility study with a “major global pharmaceutical corporation”. The study concerns testing of circVec-enhanced gene therapy with AAV in a specific therapeutic area. 2. The work is performed at Circio, and the partner pays. It has been explicitly stated that the project will be performed by Circio and is fully funded by the pharmaceutical company. 3. CNS is now a real focus area for circVec. Circio has announced that they have for the first time shown benefit in the brain/brain, and that this opens up opportunities within CNS diseases. In their presentations, CNS has also been included as a priority area along with heart and eye. 4. Relevant data will be available in 2026, including CNS-related data points. The Q1 2026 presentation shows milestones for in vivo reporter data in heart, eye & CNS, as well as further disease model data and results from the feasibility study later in 2026.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 800 | - | - | ||
| 18 867 | - | - | ||
| 3 000 | - | - | ||
| 5 963 | - | - | ||
| 1 021 | - | - |
Välittäjätilasto
Dataa ei löytynyt